Ocuphire Q3 net loss $4.5M; Nyxol NDA on track for Q4 2022

Opus Genetics, Inc.

2022-Q3 EPS reported -$0.82

Cash and equivalents of $13.9M as of Sept 30, 2022; runway into Q4 2023.
Net loss of $4.5M for Q3 2022 ($0.22 per share); R&D expenses $2.8M.
NDA submission for Nyxol (reversal of mydriasis) planned in Q4 2022.
Topline data from ZETA-1 Phase 2b trial of APX3330 expected early 2023.
U.S. patent for Nyxol extended into 2039; new KOLs appointed to advisory board.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Opus Genetics, Inc. reported financial results for quarter ended September 30, 2022.

Period: quarter ended September 30, 2022
Result: reported results

Exact text from the filing

On November 4, 2022, Ocuphire Pharma, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2022.

View on SEC.gov

31 earnings releases filed in the last 30 days. Browse all earnings releases →

Opus Genetics, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-22-040018

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.